|
An open-label expanded-access study to evaluate the safety, tolerability, and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and hepatic impairment. |
|
|
Consulting or Advisory Role - EMD Serono |
Speakers' Bureau - Amgen; Celgene; Genentech; Ipsen; Novartis; Sirtex Medical |
Research Funding - Celgene (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); NanoCarrier; Pharmacyclics; Taiho Pharmaceutical (Inst) |
|
|
Research Funding - Bayer (Inst); Lilly (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Regeneron (Inst) |
|
|
|
Stock and Other Ownership Interests - Amplimmune (I); Novavax (I) |
|
Research Funding - Celgene (Inst); Taiho Pharmaceutical (Inst) |
|
|
Honoraria - Genentech/Roche; Taiho Pharmaceutical |
Consulting or Advisory Role - Bayer |
Research Funding - Bayer; Merck (Inst) |
|
|
Consulting or Advisory Role - Lilly; Sanofi |
Speakers' Bureau - Celgene; Genentech/Roche |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); GITR (Inst); Halozyme (Inst); Ignyta (Inst); Kinex (Inst); Pfizer (Inst); VBL Therapeutics (Inst) |
|
|
Honoraria - Taiho Pharmaceutical |
Speakers' Bureau - Celgene; Lilly; Taiho Pharmaceutical |
|
|
Employment - Taiho Pharmaceutical |
|
|
Employment - Taiho Pharmaceutical |
|
|
No Relationships to Disclose |